Cargando…

Serum levels of MMP-11 correlate with clinical outcome in Chinese patients with advanced gastric adenocarcinoma

BACKGROUND: The aim of the present study was to investigate the association between serum levels of matrix metalloproteinase 11 (MMP-11) and responses to front-line chemotherapy and prognosis in advanced unresectable gastric adenocarcinoma. METHODS: Clinical data concerning 86 patients with advanced...

Descripción completa

Detalles Bibliográficos
Autores principales: Yan, Dong, Dai, Hong, Liu, Jin-Wei
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3094327/
https://www.ncbi.nlm.nih.gov/pubmed/21513571
http://dx.doi.org/10.1186/1471-2407-11-151
_version_ 1782203544767561728
author Yan, Dong
Dai, Hong
Liu, Jin-Wei
author_facet Yan, Dong
Dai, Hong
Liu, Jin-Wei
author_sort Yan, Dong
collection PubMed
description BACKGROUND: The aim of the present study was to investigate the association between serum levels of matrix metalloproteinase 11 (MMP-11) and responses to front-line chemotherapy and prognosis in advanced unresectable gastric adenocarcinoma. METHODS: Clinical data concerning 86 patients with advanced gastric adenocarcinoma (stages III c to IV), treated in Beijing Chao-Yang Hospital from 2005 to 2009, were reviewed retrospectively. Adenocarcinoma was confirmed by pathology and patients received 5-fluorouracil-based front-line combination chemotherapy with third generation chemotherapeutic agents including paclitaxel, docetaxel and oxaliplatin. The regimen was repeated every two to three weeks, and the first evaluation was carried out after three cycles. The median cycle of chemotherapy was 6 (ranging from three to twelve cycles). Serum MMP-11 protein from the 86 patients was examined using enzyme-linked-immunosorbent-assay (ELISA) prior to chemotherapy and after three cycles of chemotherapy. Serum samples from healthy individuals were used as controls. RESULTS: The response rate (RR, complete response plus partial response) to chemotherapy in the 86 patients was 44.2% (38/86). The median TTP (time to progression) and overall survival (OS) in patients who responded to chemotherapy were 6.0 and 10.0 months, respectively. The response rate to chemotherapy in patients with high levels of serum MMP-11 (42.9%; 9/21) was similar to that in patients with low levels (44.6%; 29/65) (P = 0.935). Patients with low serum levels of MMP-11 had a higher median survival time and 1-year survival rate than those with high levels (11 months vs. 8 months, 50.2% vs. 21.7%, P = 0.017), although the TTP was comparable in all patients, irrespective of serum MMP-11 level (P = 0.178). Serum MMP-11 levels were correlated with lymph node metastasis (P = 0.006). Cox multivariate regression analysis demonstrated that the serum level of MMP-11 was an independent prognostic factor for patients presenting with advanced gastric carcinoma. CONCLUSIONS: Serum levels of MMP-11 in Chinese patients with advanced gastric carcinoma were not associated with the response to front-line chemotherapy, but could play an important role in lymph node metastasis and prognosis.
format Text
id pubmed-3094327
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-30943272011-05-14 Serum levels of MMP-11 correlate with clinical outcome in Chinese patients with advanced gastric adenocarcinoma Yan, Dong Dai, Hong Liu, Jin-Wei BMC Cancer Research Article BACKGROUND: The aim of the present study was to investigate the association between serum levels of matrix metalloproteinase 11 (MMP-11) and responses to front-line chemotherapy and prognosis in advanced unresectable gastric adenocarcinoma. METHODS: Clinical data concerning 86 patients with advanced gastric adenocarcinoma (stages III c to IV), treated in Beijing Chao-Yang Hospital from 2005 to 2009, were reviewed retrospectively. Adenocarcinoma was confirmed by pathology and patients received 5-fluorouracil-based front-line combination chemotherapy with third generation chemotherapeutic agents including paclitaxel, docetaxel and oxaliplatin. The regimen was repeated every two to three weeks, and the first evaluation was carried out after three cycles. The median cycle of chemotherapy was 6 (ranging from three to twelve cycles). Serum MMP-11 protein from the 86 patients was examined using enzyme-linked-immunosorbent-assay (ELISA) prior to chemotherapy and after three cycles of chemotherapy. Serum samples from healthy individuals were used as controls. RESULTS: The response rate (RR, complete response plus partial response) to chemotherapy in the 86 patients was 44.2% (38/86). The median TTP (time to progression) and overall survival (OS) in patients who responded to chemotherapy were 6.0 and 10.0 months, respectively. The response rate to chemotherapy in patients with high levels of serum MMP-11 (42.9%; 9/21) was similar to that in patients with low levels (44.6%; 29/65) (P = 0.935). Patients with low serum levels of MMP-11 had a higher median survival time and 1-year survival rate than those with high levels (11 months vs. 8 months, 50.2% vs. 21.7%, P = 0.017), although the TTP was comparable in all patients, irrespective of serum MMP-11 level (P = 0.178). Serum MMP-11 levels were correlated with lymph node metastasis (P = 0.006). Cox multivariate regression analysis demonstrated that the serum level of MMP-11 was an independent prognostic factor for patients presenting with advanced gastric carcinoma. CONCLUSIONS: Serum levels of MMP-11 in Chinese patients with advanced gastric carcinoma were not associated with the response to front-line chemotherapy, but could play an important role in lymph node metastasis and prognosis. BioMed Central 2011-04-24 /pmc/articles/PMC3094327/ /pubmed/21513571 http://dx.doi.org/10.1186/1471-2407-11-151 Text en Copyright ©2011 Yan et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Yan, Dong
Dai, Hong
Liu, Jin-Wei
Serum levels of MMP-11 correlate with clinical outcome in Chinese patients with advanced gastric adenocarcinoma
title Serum levels of MMP-11 correlate with clinical outcome in Chinese patients with advanced gastric adenocarcinoma
title_full Serum levels of MMP-11 correlate with clinical outcome in Chinese patients with advanced gastric adenocarcinoma
title_fullStr Serum levels of MMP-11 correlate with clinical outcome in Chinese patients with advanced gastric adenocarcinoma
title_full_unstemmed Serum levels of MMP-11 correlate with clinical outcome in Chinese patients with advanced gastric adenocarcinoma
title_short Serum levels of MMP-11 correlate with clinical outcome in Chinese patients with advanced gastric adenocarcinoma
title_sort serum levels of mmp-11 correlate with clinical outcome in chinese patients with advanced gastric adenocarcinoma
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3094327/
https://www.ncbi.nlm.nih.gov/pubmed/21513571
http://dx.doi.org/10.1186/1471-2407-11-151
work_keys_str_mv AT yandong serumlevelsofmmp11correlatewithclinicaloutcomeinchinesepatientswithadvancedgastricadenocarcinoma
AT daihong serumlevelsofmmp11correlatewithclinicaloutcomeinchinesepatientswithadvancedgastricadenocarcinoma
AT liujinwei serumlevelsofmmp11correlatewithclinicaloutcomeinchinesepatientswithadvancedgastricadenocarcinoma